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Provided are his-quaternary ammonium compounds which 
are modulators of nicotinic acetylcholine receptors. Also 
provided are methods of using the compounds for modulat-
ing the function of a nicotinic acetylcholine receptor, and for 
the prevention and/or treatment of central nervous system 
disorders, substance use and/or abuse, and or gastrointestinal 
tract disorders. 
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HIS-QUATERNARY AMMONIUM SALTS AND 
METHODS FOR MODULATING NEURONAL 
NICOTINIC ACETYLCHOLINE RECEPTORS 
FIELD OF THE INVENTION 
The invention relates to his-quaternary ammonium salts 
and their use in modulating nicotinic acetylcholine recep-
tors. 
BACKGROUND OF THE INVENTION 
S(-)-nicotine (NIC) activates presynaptic and postsynap-
10 
2 
evaluated in clinical trials for cognitive enhancement and 
neuroprotective effects, potentially beneficial for disease 
states such as Alzheimer's and Parkinson's disease. 
SUMMARY OF INVENTION 
In one embodiment, compounds corresponding to the 
following structure are provided. 
X 2 8EBR 2 -R-R 1EB8X 1 (I) 
X18 and X28 are each independently an organic or 
inorganic anion. 
R is chosen from the group consisting of alkyl, substituted 
15 alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
arylalkyl, substituted arylalkyl, arylalkenyl, substituted ary-
lalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, 
tic neuronal nicotinic receptors that evoke the release of 
neurotransmitters from presynaptic terminals and that 
modulate the depolarization state of the postsynaptic neu-
ronal membrane, respectively. Thus, nicotine produces its 
effect by binding to a family of ligand-gated ion channels, 
stimulated by acetylcholine (ACh) or nicotine which causes 
the ion channel to open and cations to flux with a resulting 20 
rapid (millisecond) depolarization of the target cell. 
Neuronal nicotinic receptors are composed of two types 
substituted heterocyclic, alkoxy, alkylamine and thioalkyl. 
R 1 and R 2 are each independently five or six membered 
rings as shown in formulas (IIA) and (liB), wherein each 
ring of R 1 and R 2 has one, two or three nitrogen atoms, each 
ring of R 1 and R 2 has one quaternized nitrogen, and the ring 
atoms from R1 and R2 which are attached toR cannot both 
of subunits, a and ~' and assemble as heteromeric receptors 
with the general stoichiometry of 2a and 3~ or as homo-
meric receptors with Sa subunits. Nine subtypes of the a 
subunit (a2 to alO) and three subtypes of the~ unit (~2 to 
(~4) are found in the central nervous system. The most 
common nicotinic receptor subtype in the brain is composed 
25 be nitrogen atoms. 
of two a4 and three ~2 subunits, i.e., a4~2. These subunits 
display different, but overlapping, patterns of expression in 30 
the brain. Examples of heteromeric receptor subtypes 
include a4~2, a3~2, a3~4, a6~2, a4a5~2, a6a5~2, 
a4a6~2, a4~2~4, a3~2~4, and others. The predominant 
homomeric subtype includes a7, but other combinations 
have also been proposed. 35 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combi- 40 
nations of assemblies of subunits into functional receptor 
proteins, which affords a wide diversity of pharmacological 
specificity. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 45 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many studies. [3H]NIC 
appears to label the same sites in the brain as [3 H]ACh. It has 
been estimated that over 90% of [3 H]NIC binding in the 
brain is due to association with the heteromeric receptor that 50 
is composed of a4 and ~2 subunits. Also abundant in the 
central nervous system are the homomeric receptors labeled 
by [3H]methyllycaconitine (MLA), which has high affinity 
for the a7 nicotinic receptor subtype. Nicotinic receptor 
subtypes can be studied using functional assays, such as 55 
NIC-evoked neurotransmitter release (e.g., [3H]dopamine 
(DA) release, [3 H]norepinephrine (NE) release, [3H]sero-
tonin (5-HT) release, [3 H]gamma-aminobutyric acid 
(GABA) release and [3 H]glutamate release) from super-
fused rat brain slices. Nicotinic receptors are located in the 60 
cell body and terminal areas of these neurotransmitter sys-
tems. NIC facilitates neurotransmitter release from nerve 
terminals. 
(IIA) 
(liB) 
A 1 is carbon or nitrogen, provided that when A 1 joins a 
ring atom with an unsaturated bond or is a nitrogen, R3 is 
absent, and when A 1 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R3 and R4 are absent. 
A2 is carbon or nitrogen, provided that when A2 joins a 
ring atom with an unsaturated bond or is a nitrogen, R4 is 
absent, and when A2 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R4 and Rs are absent. 
A3 is carbon or nitrogen, provided that when A3 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 6 is 
absent, and when A3 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R6 and R7 are absent. 
A 4 is carbon or nitrogen, provided that when A 4 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 8 is 
absent, and when A 4 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R 8 and R9 are absent. 
As is carbon or nitrogen, provided that when As joins a 
ring atom with an unsaturated bond or is a nitrogen, R 10 is 
absent, and when As joins a ring atom with an unsaturated 
bond and is a nitrogen, both R 10 and R 11 are absent. 
The structural and functional diversity of central nervous 
system nicotinic receptors has stimulated a great deal of 
interest in developing novel, subtype-selective agonists and/ 
or antagonists. Some of these agonists are currently being 
A 6 is carbon or nitrogen, provided that when A 6 joins a 
65 ring atom with an unsaturated bond or is a nitrogen, R12 is 
absent, and when A6 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R12 and R13 are absent. 
US 9,540,327 B2 
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A7 is carbon or nitrogen, provided that when A7 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 14 is 
absent, and when A7 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R14 and R15 are absent. 
A 8 is carbon or nitrogen, provided that when A 8 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 15 is 
absent, and when A 8 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R15 and R16 are absent. 
4 
R 6 together with A 2 and A3, or R 6 and R 8 together with A3 
andA4, or R16 and R17 together withA8 andA9, or R17 and 
R 18 together with A9 and A IO independently form a three to 
eight member cyclolkane, substituted cycloalkane, cycloalk-
ene, substituted cycloalkene, aryl, substituted aryl, hetero-
cycle with one to three hetero atoms in the ring, or substi-
tuted heterocycle with one to three hetero atoms in the ring; 
and when all of the bonds to the ring ammonium nitrogen are 
saturated, then any ofR3, R4, R5, R6, R7, R8, R9, RIO, R11 , A
9 is carbon or nitrogen, provided that when A9 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 17 is 
absent, and when A9 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R 17 and R 18 are absent. 
10 Rl2, Rl3, R14, R1s, R16, Rl7, R18, R19, R2o, R21 or R22 which 
is attached to the ammonium nitrogen is a straight or 
branched alkyl group of four carbons or fewer. 
A IO is carbon or nitrogen, provided that when A IO joins a 
ring atom with an unsaturated bond or is a nitrogen, R 19 is 
absent, and when A IO joins a ring atom with an unsaturated 
bond and is a nitrogen, both R19 and R20 are absent. 
In another embodiment, a composition is provided com-
prising a pharmaceutically acceptable carrier and a com-
15 pound as described above. 
In another embodiment, a method is provided for selec-
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effec-
tive amount of a compound as described above to a mam-
A 11 is carbon or nitrogen, provided that when A 11 joins a 
ring atom with an unsaturated bond or is a nitrogen, R21 is 
absent, and when A 11 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R21 and R22 are absent. 
R3 R4 Rs R6 R7 R8 R9 RIO R11 R12 and R13 or R14 
20 malian subject in need thereof. 
R1s R' 16 'Rl7' R1s RI9 R2o R21 :mdR22 ~hen present ar~ 
' ' ' ' ' ' ' ' ' each independently selected from hydrogen, alkyl, substi-
In another embodiment, a method is provided for pre-
venting and/or treating a central nervous system associated 
disorder comprising administering a therapeutically effec-
tive amount of a compound as described above to a mam-tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub-
stituted alkenyl, alkynyl, substituted alkynyl, aryl, substi-
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, 
substituted arylalkyl, arylalkenyl, substituted arylalkenyl, 
arylalkynyl, substituted arylalkynyl, heterocyclic, substi-
tuted heterocyclic, halo, cyano, nitro, SOY1, S02Y
1, 
S020Y
1 or S02NHY
1, where Y1 is selected from hydrogen, 
lower alkyl, alkenyl, alkynyl or aryl, and where Y1 is not 
hydrogen in SOY1 and ifY1 is alkenyl or alkynyl, the site of 
unsaturation is not conjugated with a heteroatom; COY2, 
where Y2 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkoxy, alkenyl, substi-
tuted alkenyl, alkynyl, substituted alkynyl, aryl, substituted 
aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted 
arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, 
substituted arylalkynyl, heterocyclic, or substituted hetero-
cyclic, and where ifY2 comprises alkenyl or alkynyl, the site 
25 malian subject in need thereof. 
In another embodiment, a method is provided for pre-
venting and/or treating substance use and/or abuse compris-
ing administering a therapeutically effective amount of a 
compound as described above to a mammalian subject in 
30 need thereof. 
In another embodiment, a method is provided for pre-
venting and/or treating gastrointestinal tract disorders com-
prising administering a therapeutically effective amount of a 
compound as described above to a mammalian subject in 
35 need thereof. 
Other methods, features and advantages of the present 
invention will be or become apparent to one with skill in the 
art upon examination of the following detailed descriptions. 
It is intended that all such additional methods, features and 
40 advantages be included within this description, be within the 
scope of the present invention, and be protected by the 
accompanying claims. 
of unsaturation is not conjugated with the carbonyl group; 
OY3, where Y3 is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal- 45 
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, substituted acyl, alkylsulfonyl, 
arylsulfonyl, heterocyclic, or substituted heterocyclic, where 
if Y3 comprises alkenyl or alkynyl, the site of unsaturation 
is not conjugated with the oxygen; NY4Y5, where Y4 and Y5 50 
are each independently selected from hydrogen, alkyl, sub-
stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub-
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, sub-
stituted arylalkyl, arylalkenyl, substituted arylalkenyl, ary- 55 
lalkynyl, substituted arylalkynyl, acyl, substituted acyl, 
alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted het-
erocyclic, where if Y4 or Y5 comprises alkenyl or alkynyl, 
the site of unsaturation is not conjugated with the nitrogen; 
SY6, where Y6 is selected from hydrogen, alkyl, substituted 60 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, heterocyclic, or substituted heterocy- 65 
clic, and where ifY6 comprises alkenyl or alkynyl, the site 
ofunsaturation is not conjugated with the sulfur; or R5 and 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the concentration dependent inhibition by 
compound GZ527B on the effect of nicotine to evoke 
[3H]dopamine release. 
DETAILED DESCRIPTION OF INVENTION 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, 
and is in no way intended to limit the scope of the present 
invention as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms "a," "an," and "the" include plural 
references unless the context clearly dictates otherwise. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meanings as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. All publications cited herein are incor-
porated herein by reference in their entirety for the purpose 
US 9,540,327 B2 
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of describing and disclosing the methodologies, reagents, 
and tools reported in the publications that might be used in 
connection with the invention. Nothing herein is to be 
construed as an admission that the invention is not entitled 
to antedate such disclosure by virtue of prior invention. 
The term "nicotinic acetylcholine receptor" refers to the 
endogenous acetylcholine receptor having binding sites for 
acetylcholine which also bind to nicotine. The term "nico-
tinic acetylcholine receptor" includes the term "neuronal 
nicotinic acetylcholine receptor." 
The terms "subtype of nicotinic acetylcholine receptor," 
and "nicotinic acetylcholine receptor subtype" refer to vari-
ous subunit combinations of the nicotinic acetylcholine 
receptor, and may refer to a particular homomeric or het-
eromeric complex, or multiple homomeric or heteromeric 
complexes. 
The term "agonist" refers to a substance which interacts 
with a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term "partial agonist" refers to a substance which 
interacts with and activates a receptor to a lesser degree than 
an agonist. 
The term "antagonist" refers to a substance which inter-
acts with and decreases the extent or duration of a physi-
ological response of that receptor. 
The terms "disorder," "disease," and "condition" are used 
inclusively and refer to any status deviating from normal. 
The term "central nervous system associated disorders" 
includes any cognitive, neurological, and mental disorders 
causing aberrant or pathological neural signal transmission, 
such as disorders associated with the alteration of normal 
neurotransmitter release in the brain. 
6 
The term "arylalkenyl" refers to aryl-substituted alkenyl 
groups, and "substituted arylalkenyl" refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
above. 
The term "arylalkynyl" refers to aryl-substituted alkynyl 
groups, and "substituted arylalkynyl" refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The term "heterocyclic" refers to cyclic moieties contain-
10 ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and "substituted heterocyclic" 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
15 
The term "acyl" refers to alkyl-carbonyl groups, and 
"substituted acyl" refers to acyl groups further bearing one 
or more substituents as set forth above. 
The term "halogen" refers to fluoride, chloride, bromide 
or iodide groups. 
20 
It is understood that in all substituted groups defined 
above, polymers arrived at by defining substituents with 
further substituents to themselves (e.g. substituted aryl hav-
ing a substituted aryl group as a substituent which is itself 
substituted with a substituted aryl group, etc.) are not 
25 
intended for inclusion herein. In such cases, the maximum 
number of such substituents is three. That is to say that each 
of the above definitions is constrained by a limitation that, 
for example, substituted aryl groups are limited to -substi-
tuted aryl-(substituted aryl)-substituted aryl. 
30 
Compounds of the present invention are tris-quaternary 
ammonium salts corresponding to Formula (I): 
X 2 8EBR2-R-R1EB8X 1 (I) 
The term "lower alkyl" refers to straight or branched 
35 
chain alkyl radicals having in the range of 1 to 4 carbon 
X18 and X28 are each independently an organic or 
inorganic anion. 
R is chosen from the group consisting of alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
arylalkyl, substituted arylalkyl, arylalkenyl, substituted ary-
atoms. 
The term "alkyl" refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and "substituted alkyl" 
refers to alkyl radicals further bearing one or more substitu-
ents including, but not limited to, hydroxy, alkoxy (of a 
lower alkyl group), mercapto (of a lower alkyl group), aryl, 
heterocyclic, halogen, trifluoromethyl, cyano, nitro, amino, 
carboxyl, carbamate, sulfonyl, and sulfonamide. 
40 lalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, 
substituted heterocyclic, alkoxy, alkylamine and thioalkyl. 
The term "cycloalkyl" refers to cyclic ring-containing 
moieties containing 3 to 8 carbon atoms, and "substituted 
cycloalkyl" refers to cycloalkyl moieties further bearing one 
R 1 and R 2 are each independently five or six membered 
rings as shown in formulas (IIA) and (liB), wherein each 
ring of R 1 and R 2 has one, two or three nitrogen atoms, each 
45 ring of R 1 and R 2 has one quaternized nitrogen, and the ring 
atoms from R1 and R2 which are attached toR cannot both 
or more substituents as set forth above. 
The term "alkenyl" refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon 50 
double bond and having 2 to 19 carbon atoms, and "substi-
tuted alkenyl" refers to alkenyl groups further bearing one or 
more substituents as set forth above. 
The term "alkynyl" refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon 55 
triple bond and having 2 to 19 carbon atoms, and "substi-
tuted alkynyl" refers to alkynyl moieties further bearing one 
or more substituents as set forth above. 
The term "aryl" refers to aromatic groups having 6 to 24 
carbon atoms, and "substituted aryl" refers to aryl groups 60 
further bearing one or more substituents as set forth above. 
The term "alkylaryl" refers to alkyl-substituted aryl 
groups, and "substituted alkylaryl" refers to alkylaryl groups 
further bearing one or more substituents as set forth above. 
The term "arylalkyl" refers to aryl-substituted alkyl 65 
groups, and "substituted arylalkyl" refers to arylalkyl groups 
further bearing one or more substituents as set forth above. 
be nitrogen atoms. 
(!lA) 
(liB) 
A 1 is carbon or nitrogen, provided that when A 1 joins a 
ring atom with an unsaturated bond or is a nitrogen, R3 is 
US 9,540,327 B2 
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absent, and when A 1 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R3 and R4 are absent. 
A2 is carbon or nitrogen, provided that when A2 joins a 
ring atom with an unsaturated bond or is a nitrogen, R4 is 
absent, and when A2 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R4 and Rs are absent. 
8 
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, acyl, substituted acyl, alkylsulfonyl, 
arylsulfonyl, heterocyclic, or substituted heterocyclic, where 
if Y3 comprises alkenyl or alkynyl, the site of unsaturation 
is not conjugated with the oxygen; NY4Ys, where Y4 and ys 
are each independently selected from hydrogen, alkyl, sub-
stituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub-
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, sub-
A3 is carbon or nitrogen, provided that when A3 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 6 is 
absent, and when A3 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R6 and R7 are absent. 
A 4 is carbon or nitrogen, provided that when A 4 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 8 is 
absent, and when A 4 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R 8 and R9 are absent. 
10 stituted arylalkyl, arylalkenyl, substituted arylalkenyl, ary-
lalkynyl, substituted arylalkynyl, acyl, substituted acyl, 
alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted het-
erocyclic, where if Y4 or ys comprises alkenyl or alkynyl, 
As is carbon or nitrogen, provided that when As joins a 15 
ring atom with an unsaturated bond or is a nitrogen, RIO is 
absent, and when As joins a ring atom with an unsaturated 
bond and is a nitrogen, both RIO and R 11 are absent. 
A 6 is carbon or nitrogen, provided that when A 6 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 12 is 20 
absent, and when A 6 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R12 and R13 are absent. 
A7 is carbon or nitrogen, provided that when A7 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 14 is 
absent, and when A7 joins a ring atom with an unsaturated 25 
bond and is a nitrogen, both R14 and R1s are absent. 
the site of unsaturation is not conjugated with the nitrogen; 
SY6, where Y6 is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
kyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub-
stituted arylalkynyl, heterocyclic, or substituted heterocy-
clic, and where ifY6 comprises alkenyl or alkynyl, the site 
ofunsaturation is not conjugated with the sulfur; or Rs and 
R 6 together with A 2 and A3, or R 6 and R 8 together with A3 
andA4, or R16 and R17 together withA8 andA9, or R17 and 
R 18 together with A9 and A IO independently form a three to 
eight member cyclolkane, substituted cycloalkane, cycloalk-
ene, substituted cycloalkene, aryl, substituted aryl, hetero-
cycle with one to three hetero atoms in the ring, or substi-
tuted heterocycle with one to three hetero atoms in the ring; 
A 8 is carbon or nitrogen, provided that when A 8 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 1s is 
absent, and when A 8 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R1s and R16 are absent. 
A9 is carbon or nitrogen, provided that when A9 joins a 
ring atom with an unsaturated bond or is a nitrogen, R 17 is 
absent, and when A9 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R 17 and R 18 are absent. 
30 and when all of the bonds to the ring ammonium nitrogen are 
saturated, then any ofR3, R4, Rs, R6, R7, R8, R9, RIO, R11 , 
Rl2, Rl3, R14' R1s, R16' Rl7, R18' R19' R2o, R21 or R22 which 
is attached to the ammonium nitrogen is a straight or 
A IO is carbon or nitrogen, provided that when A 10 joins a 35 
ring atom with an unsaturated bond or is a nitrogen, R 19 is 
absent, and when A IO joins a ring atom with an unsaturated 
bond and is a nitrogen, both R19 and R20 are absent. 
A 11 is carbon or nitrogen, provided that when A 11 joins a 
ring atom with an unsaturated bond or is a nitrogen, R21 is 40 
absent, and when A 11 joins a ring atom with an unsaturated 
bond and is a nitrogen, both R21 and R22 are absent. 
R3, R4, Rs, R6, R7, R8, R9, RIO, R11 , R12, and R13 or R14, 
R1s, R16, R17, R18, R19, R20, R21 , and R22, when present, are 
each independently selected from hydrogen, alkyl, substi- 45 
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub-
stituted alkenyl, alkynyl, substituted alkynyl, aryl, substi-
tuted aryl, alkylaryl, substituted alkylaryl, arylalkyl, 
substituted arylalkyl, arylalkenyl, substituted arylalkenyl, 
arylalkynyl, substituted arylalkynyl, heterocyclic, substi- 50 
tuted heterocyclic, halo, cyano, nitro, SOY1, S02Y
1, 
S020Y
1 or S02NHY
1, where Y1 is selected from hydrogen, 
lower alkyl, alkenyl, alkynyl or aryl, and where Y1 is not 
hydrogen in SOY1 and ifY1 is alkenyl or alkynyl, the site of 
unsaturation is not conjugated with a heteroatom; COY2, 55 
where Y2 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkoxy, alkenyl, substi-
tuted alkenyl, alkynyl, substituted alkynyl, aryl, substituted 
aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted 
arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, 60 
substituted arylalkynyl, heterocyclic, or substituted hetero-
cyclic, and where ifY2 comprises alkenyl or alkynyl, the site 
of unsaturation is not conjugated with the carbonyl group; 
OY3, where Y3 is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 65 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylal-
branched alkyl group of four carbons or fewer. 
For example, R1 and R2 include pyrrole, pyrrolidine, 
pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, 
piperidine, quinoline, tetrahydroquinoline, isoquinoline, tet-
rahydroisoquinoline, pyrazine, piperazine, pyridazine, and 
triazine. 
As another example, R3, R4, Rs, R6, R7, R8, R9, RIO, R11 , 
Rl2, Rl3, R14' R1s, R16' Rl7, R18' R19' R2o, R21 and R22, 
include hydrogen, methyl, ethyl, propyl, butyl, trifluorom-
ethyl, pyrrolidine, N-alkyl pyrrolidine (for example where 
the alkyl chain is methyl, ethyl or propyl), unsaturated 
pyrrolidine, unsaturated N-alkyl pyrrolidine (for example 
where the alkyl chain is methyl, ethyl or propyl), aziridine, 
N-methyl aziridine, azetidine, N-methyl azetidine, unsatu-
rated azetidine, unsaturated N-methyl azetidine, piperidine, 
N-methyl piperidine, unsaturated piperidine, unsaturated 
N-methyl piperidine, azepane, N-methyl azepane, unsatu-
rated azepane, unsaturated N-methyl azepane, azocane, 
N-methyl azocane, unsaturated azocane, unsaturated 
N-methyl azocane, 1-aza-bicyclo [3.2.1] octane, 1-aza-bi-
cyclo [2.2.1] heptane, 8-methyl-8-aza-bicyclo [3.2.1] 
octane, 1-aza-tricyclo [3.3.1.1 3.7] decane, methyl 
cycloalkyl, methyl substituted cycloalkyl, methyl pyrroli-
dine, methyl N-alkyl pyrrolidine (for example where the 
alkyl chain is methyl, ethyl or propyl), methyl unsaturated 
pyrrolidine, methyl unsaturated N-alkyl pyrrolidine (for 
example where the alkyl chain is methyl, ethyl or propyl), 
methyl aziridine, methyl N-methyl aziridine, methyl azeti-
dine, methyl N-methyl azetidine, methyl unsaturated azeti-
dine, methyl unsaturated N-methyl azetidine, methyl piperi-
dine, methyl N-methyl piperidine, methyl unsaturated 
piperidine, methyl unsaturated N-methyl piperidine, methyl 
azepane, methyl N-methyl azepane, methyl unsaturated 
azepane, methyl unsaturated N-methyl azepane, methyl azo-
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cane, methyl N-methyl azocane, methyl unsaturated azo-
cane, methyl unsaturated N-methyl azocane, methyl-1-aza-
bicyclo [3.2.1] octane, methyl-1-aza-bicyclo [2.2.1] 
heptane, 8-methyl-8-aza-bicyclo [3 .2.1] octane, and methyl-
1-aza-tricyclo [3.3.1.1 3 •7 ] decane. 
As a further example, when R5 and R6 together with A2 
andA3 , orR6 andR8 togetherwithA3 andA4 , orR16 andR17 
together with A 8 andA9 , orR 17 and R 19 together withA9 and 
A IO independently form a three to eight-membered ring, that 
ring may be a heterocycle containing up to three hetero 10 
atoms (for example nitrogen, oxygen or sulfur) in the ring, 
and further may be substituted with one or more substitu-
ents. For example, possible rings include benzene, pyridine, 
pyran, indene, isoindene, benzofuran, isobenzofuran, benzo 
15 
[b ]thiophene, benzo[ c ]thiophene, indole, indolenine, isoin-
dole, cyclopental[b ]pyridine, pyrano[3,4-b ]pynrole, inda-
zole, indoxazine, benzoxazole, anthranil naphthalene, 
tetralin, decalin, chromene, coumarin, chroman-4-one, iso-
coumarin, isochromen-3-one, quinoline, isoquinoline, cin- 20 
noline, quinazoline, naphthyrdine, pyrido[3,4-b]-pyridine, 
pyridol[3,2-b ]pyridine, pyrido[ 4,3,-b ]-pyridine, benzox-
azine, anthracene, phenanthrene, phenalene, fluorene, cara-
zole, xanthene, acnidine, octahydro-[l]pyridine, 1-methyl-
octahydro-[ !]pyridine, octahydroindole, 25 
1-methyloctahydro-indole, octahydro-cyclopenta[b ]pyrrole, 
1-methyloctahydro-cyclopenta[b ]pyrrole, decahydroquino-
line, and 1-methyldecahydroquinoline. 
10 
In another embodiment, the compound of Formula (I) is 
defined wherein R is -(CH2 ) 12-, R 
1 and R2 are pyridinium 
rings; and wherein for R\ A3 is nitrogen, R7 is methyl, R11 
is hydrogen or methyl, and X1 is bromide or iodide; and 
wherein for R2 , A1 is nitrogen, R7 and R11 is hydrogen, 
methyl or 1-methyl-2-pyrrolidinyl, and X2 is bromide or 
iodide. 
Exemplary compounds of the present invention include: 
N,N'-dimethyl-2,2'-(1, 12-dodecanediyl)bispyridinium diio-
dide; 
N,N'-dimethyl-3,3'-(1, 12-dodecanediyl)bispyridinium diio-
dide; 
N,N'-dimethyl-4,4'-(1, 12-dodecanediyl)bispyridinium diio-
dide; 
N,N'-dimethyl-3,3'-(1, 12-dodecanediyl)bis-5-methylpyri-
dinium diiodide; 
1-methyl-3-(12-(3-methylpyridin-1-ium -1-yl)dodecyl)pyri-
din-1-ium mono-bromide mono-iodide; 
3,5-dimethyl-1-(12-(1-methylpyridin-1-ium-3-yl)dodecyl) 
pyridin-1-ium mono-bromide mono-iodide; 
(S)-1-methyl-3-(12-(3-(1-methylpyrrolidin-2-yl)pyridin-1-
ium-1-yl)dodecyl)pyridin-1-ium mono-bromide mono-
iodide; and 
1-methyl-3-(12-(pyridin-1-ium-1-yl)dodecyl)pyridin-1-ium 
mono-bromide mono-iodide. 
The compounds of the present invention may contain one 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as well as racemic 
mixtures. The compounds can be separated into substan-
tially optically pure compounds. 
The compounds of the invention are nicotinic acetylcho-
line receptor agents. Thus, they may augment or inhibit 
[
3 H]nicotine binding, [3H]MLA binding, evoke or inhibit 
neurotransmitter release, and/or evoke or inhibit the flux of 
ions through the nicotinic receptor. 
Moreover, the compounds of the invention may act either 
at presynaptic sites or postsynaptic sites, for example, at a 
postsynaptic acetylcholine receptor containing an a7 sub-
unit. When acting at a postsynaptic site, neurotransmitter 
X18 and X28, for example, include F-, Cl-, Br-, I-, 
N02 -, HS04 -, S04 -, HP04 -, PO/-, methanesulfonate, 30 
trifluromethane sulfate, p-toluenesulfonate, benzenesul-
fonate, salicylate, proprionate, ascorbate, aspartate, fumar-
ate, galactarate, maleate, citrate, glutamate, glycolate, lac-
tate, malate, maleate, tartrate, oxalate, succinate, or similar 
pharmaceutically acceptable organic acid addition salts, 35 
including the pharmaceutically acceptable salts listed in the 
Journal of Pharmaceutical Sciences volume 66, page 2, 
1977, which are hereby incorporated by reference. The 
above salt forms may be in some cases hydrates or solvates 
with alcohols and other solvents. 40 release per se is not altered. Rather, the compounds of the 
invention may act by interacting with a postsynaptic ace-
tylcholine receptor to change the membrane potential of the 
cell, thereby increasing or decreasing the likelihood of firing 
an action potential. Alternatively, interaction of a compound 
In a compound of Formula (I), preferably R1 and R2 are 
substituted, six-membered, aromatic rings. More preferably, 
R 1 and R 2 are substituted pyridinium rings, wherein A\ A 2 , 
A3 or A 4 is nitrogen. 
In a compound of Formula (I), preferably R3 is absent. 
In a compound of Formula (I), preferably R4 , R5 , R6 , R7 , 
R8 , R9 , RIO, R11 , R12 or R13 is absent or is hydrogen, alkyl 
or 1-methyl-2-pyrrolidinyl. More preferably, R4 , R5 , R6 , R7 , 
R8 , R9 , RIO, R11 , R12 or R13 is absent or is hydrogen, methyl 
or 1-methyl-2-pyrrolidinyl. 
In a compound of Formula (I), preferably R is alkyl. More 
preferably, R is -(CH2 ) 12-. 
In a compound of Formula (I), preferably X18 and X28 
are halogens. More preferably, X18 and X28 are bromide or 
iodide. 
In one embodiment, the compound of Formula (I) is 
defined wherein R is -(CH2 ) 12-, R 
1 and R 2 are pyridinium 
rings, A2 is nitrogen, R5 is methyl, and X1 and X2 are 
bromide or iodide. 
In another embodiment, the compound of Formula (I) is 
defined wherein R is -(CH2 ) 12-, R 
1 and R 2 are pyridinium 
rings, A3 is nitrogen, R7 is methyl, R11 is hydrogen or 
methyl, and X1 and X2 are bromide or iodide. 
In another embodiment, the compound of Formula (I) is 
defined wherein R is -(CH2 ) 12-, R 
1 and R 2 are pyridinium 
rings, A4 is nitrogen, R9 is methyl, and X1 and X2 are 
bromide or iodide. 
45 of the invention with a postsynaptic acetylcholine receptor 
may result in the alteration of one or more second messenger 
systems within the cell so as to decrease or increase the 
nicotinic cholinergic response. 
In one embodiment, the present invention relates to a 
50 method for selectively modulating the function of a nicotinic 
acetylcholine receptor comprising administering to a mam-
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or 
55 more subtypes of nicotinic acetylcholine receptor. The com-
pound of Formula (I) may act as an against or partial agonist 
of nicotinic acetylcholine receptor function. Hence the com-
pound of Formula (I) may increase or prolong the release of 
a neurotransmitter from a central nervous system tissue. The 
60 neurotransmitter affected may include dopamine, norepi-
nephrine, serotonin, gamma-aminobutryic acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act as 
an antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
65 or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of 
Formula (I) may act by decreasing stimulant-evoked neu-
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rotransmitter release. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-amin-
obutryic acid, or glutamate. Alternatively, the compound of 
Formula (I) may act by interacting with a postsynaptic 
acetylcholine receptor to change the membrane potential of 
the cell thereby increasing or decreasing the likelihood of 
firing an action potential, or to alter one or more second 
messenger systems within the cell so as to decrease or 
increase the nicotinic cholinergic response. 
In another embodiment, the present invention is directed 10 
to a method for preventing and/or treating a central nervous 
system associated disorder comprising administering to a 
mammalian subject in need thereof a therapeutically effec-
tive amount of a compound of Formula (I). In such a 
method, the compound of Formula (I) may selectively bind 15 
to one or more subtypes of nicotinic acetylcholine receptor. 
The compound of Formula (I) may act as an against or 
partial agonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may increase or prolong 
the release of a neurotransmitter from a central nervous 20 
system tissue. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutryic 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act as an antagonist of nicotinic acetylcholine 
receptor function. Hence the compound of Formula (I) may 25 
decrease the extent or duration of the release of a neurotrans-
12 
rotransmitter release. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-amin-
obutryic acid, or glutamate. Alternatively, the compound of 
Formula (I) may act by interacting with a postsynaptic 
acetylcholine receptor to change the membrane potential of 
the cell thereby increasing or decreasing the likelihood of 
firing an action potential, or to alter one or more second 
messenger systems within the cell so as to decrease or 
increase the nicotinic cholinergic response. 
The conditions of substance use and/or abuse treated 
according to the method of the present invention include 
nicotine abuse (including use in smoking cessation therapy), 
nicotine intoxication, amphetamine abuse, methamphet-
amine abuse, MDMA (methylenedioxymethamphetamine) 
abuse, methylphenidate abuse, cocaine abuse, or alcohol 
abuse. 
In another embodiment, the present invention is directed 
to a method for preventing and/or treating gastrointestinal 
tract disorders comprising administering to a mmalian 
subject in need thereof a therapeutically effective amount of 
a compound of Formula (I). In such a method, the compound 
of Formula (I) may selectively bind to one or more subtypes 
of nicotinic acetylcholine receptor. The compound of For-
mula (I) may act as an agonist or partial agonist of nicotinic 
acetylcholine receptor function. Hence the compound of 
Formula (I) may increase or prolong the release of a neu-
rotransmitter from a central nervous system tissue, or may 
increase or prolong the release of a neurotransmitter from a 
peripheral nervous system tissue, or may act directly on a 
mitter from a central nervous system tissue. In this regard, 
the compound of Formula (I) may act by decreasing stimu-
lant-evoked neurotransmitter release. The neurotransmitter 
affected may include dopamine, norepinephrine, serotonin, 
gamma-aminobutryic acid, or glutamate. Alternatively, the 
compound of Formula (I) may act by interacting with a 
postsynaptic acetylcholine receptor to change the membrane 
potential of the cell thereby increasing or decreasing the 
likelihood of firing an action potential, or to alter one or 
more second messenger systems within the cell so as to 
decrease or increase the nicotinic cholinergic response. 
30 gastrointestinal tract tissue. The neurotransmitter affected 
may include dopamine, norepinephrine, serotonin, gamma-
aminobutryic acid, or glutamate. Alternatively, the com-
pound of Formula (I) may act as an antagonist of nicotinic 
acetylcholine receptor function. Hence the compound of 
Central nervous system disorders which may be treated 
according to the method of the present invention include 
Alzheimer's disease, dementia, cognitive dysfunctions (in-
cluding disorders of attention, focus and concentration), 
attention deficit disorders, affective disorders, extrapyrami-
dal motor function disorders, Parkinson's disease, progres-
sive supramolecular palsy, Huntington's disease, Gilles de Ia 
Tourette syndrome, tardive dyskinesia, neuroendocrine dis-
orders, dysregulation of food intake, disorders of nocicep-
tion, pain, mood and emotional disorders, depression, panic 
anxiety, psychosis, schizophrenia, or epilepsy. 
35 Formula (I) may decrease the extent or duration of the 
release of a neurotransmitter from a central nervous system 
tissue, or may decrease the extent or duration of the release 
of a neurotransmitter from a peripheral nervous system 
tissue, or may act directly on a gastrointestinal tract tissue. 
40 In this regard, the compound of Formula (I) may act by 
decreasing stimulant-evoked neurotransmitter release. The 
neurotransmitter affected may include dopamine, norepi-
nephrine, serotonin, gamma-aminobutryic acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act by 
45 interacting with a postsynaptic acetylcholine receptor to 
change the membrane potential of the cell thereby increasing 
or decreasing the likelihood of firing an action potential, or 
to alter one or more second messenger systems within the 
In yet another embodiment, the present invention is 
directed to a method for preventing and/or treating substance 50 
use and/or abuse comprising administering to a mmalian 
subject in need thereof a therapeutically effective amount of 
a compound of Formula (I). In such a method, the compound 
of Formula (I) may selectively bind to one or more subtypes 
of nicotinic acetylcholine receptor. The compound of For- 55 
mula (I) may act as an against or partial agonist of nicotinic 
acetylcholine receptor function. Hence the compound of 
Formula (I) may increase or prolong the release of a neu-
rotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi- 60 
nephrine, serotonin, gma-aminobutryic acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act as 
an antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 65 
nervous system tissue. In this regard, the compound of 
Formula (I) may act by decreasing stimulant-evoked neu-
cell so as to decrease or increase the nicotinic cholinergic 
response. 
Gastrointestinal disorders which may be treated according 
to the method of the present invention include irritable 
bowel syndrome, colitis, diarrhea, constipation, gastric acid 
secretion or ulcers. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along with suit-
able carriers or excipients, as is well known in the art. For 
example, a pharmaceutical composition of the invention 
may include a conventional additive, such as a stabilizer, 
buffer, salt, preservative, filler, flavor enhancer and the like, 
as known to those skilled in the art. Exemplary buffers 
include phosphates, carbonates, citrates and the like. Exem-
plary preservatives include EDTA, EGTA, BHA, BHT and 
the like. 
An effective amount of such agents can readily be deter-
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro-
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priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e.g., Gennaro, A. R., ed. 
(1995) Remington's Pharmaceutical Sciences. 
Suitable routes of administration may, for example, 
include oral, rectal, transmucosal, nasal, or intestinal admin-
istration and parenteral delivery, including intramuscular, 
subcutaneous, intramedullary injections, as well as intrath-
ecal, direct intraventricular, intravenous, intraperitoneal, 
intranasal, or intraocular injections. In addition, the agent or 
composition thereof may be administered sublingually or via 10 
a spray, including a sublingual tablet or a sublingual spray. 
The agent or composition thereof may be administered in a 
local rather than a systemic marmer. For example, a suitable 
agent can be delivered via injection or in a targeted drug 
delivery system, such as a depot or sustained release for- 15 
mulation. 
14 
Pharmaceutical preparations for oral administration 
include push-fit capsules made of gelatin, as well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The push-fit capsules can contain the 
active ingredients in admixture with filler such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium stearate and, optionally, stabilizers. In soft cap-
sules, the active compounds may be dissolved or suspended 
in suitable liquids, such as fatty oils, liquid paraffin, or liquid 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dos-
ages suitable for such administration. 
In one embodiment, the compounds of the present inven-
tion can be administered transdermally, such as through a 
skin patch, or topically. In one aspect, the transdermal or 
topical formulations of the present invention can addition-
ally comprise one or multiple penetration enhancers or other 
effectors, including agents that enhance migration of the 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods well-known in 
the art, such as by conventional mixing, dissolving, granu-
lating, dragee-making, levigating, emulsifYing, encapsulat-
ing, entrapping, or lyophilizing processes. As noted above, 
the compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 
into preparations for pharmaceutical use. 
20 delivered compound. Transdermal or topical administration 
could be preferred, for example, in situations in which 
location specific delivery is desired. 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently deliv-
Proper formulation is dependent upon the route of admin-
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in 
physiologically compatible buffers such as Hanks' solution, 
Ringer's solution, or physiological saline buffer. For trans-
mucosal or nasal administration, penetrants appropriate to 
the barrier to be permeated are used in the formulation. Such 
penetrants are generally known in the art. In a preferred 
embodiment of the present invention, the present com-
pounds are prepared in a formulation intended for oral 
administration. For oral administration, the compounds can 
be formulated readily by combining the active compounds 
with pharmaceutically acceptable carriers well known in the 
art. Such carriers enable the compounds of the invention to 
25 ered in the form of an aerosol spray presentation from 
pressurized packs or a nebulizer, with the use of a suitable 
propellant, e.g., dichlorodifluoromethane, trichlorofluo-
romethane, dichlorotetrafluoroethane, carbon dioxide, or 
any other suitable gas. In the case of a pressurized aerosol, 
30 the appropriate dosage unit may be determined by providing 
a valve to deliver a metered amount. Capsules and cartridges 
of, for example, gelatin, for use in an inhaler or insufflator 
may be formulated. These typically contain a powder mix of 
the compound and a suitable powder base such as lactose or 
35 starch. 
Compositions formulated for parenteral administration by 
injection, e.g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, with an added preservative. The 
compositions may take such forms as suspensions, solu-
tions, or emulsions in oily or aqueous vehicles, and may 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Formulations for parenteral admin-
istration include aqueous solutions or other compositions in 
be formulated as tablets, pills, dragees, capsules, liquids, 40 
gels, syrups, slurries, suspensions and the like, for oral 
ingestion by a subject. The compounds may also be formu-
lated in rectal compositions such as suppositories or reten-
tion enemas, e.g., containing conventional suppository bases 
such as cocoa butter or other glycerides. 45 water-soluble form. 
Pharmaceutical preparations for oral use can be obtained 
as solid excipients, optionally grinding a resulting mixture, 
and processing the mixture of granules, after adding suitable 
auxiliaries, if desired, to obtain tablets or dragee cores. 
Suitable excipients are, in particular, fillers such as sugars, 50 
including lactose, sucrose, marmitol, or sorbitol; cellulose 
preparations such as, for example, maize starch, wheat 
starch, rice starch, potato starch, gelatin, gum tragacanth, 
methyl cellulose, hydroxypropylmethyl-cellulose, sodium 
carboxymethylcellulose, and/or polyvinylpyrrolidone 55 
(PVP). If desired, disintegrating agents may be added, such 
as the cross-linked polyvinyl pyrrolidone, agar, or alginic 
acid or a salt thereof such as sodium alginate. Also, wetting 
agents such as sodium dodecyl sulfate may be included. 
Dragee cores are provided with suitable coatings. For this 60 
purpose, concentrated sugar solutions may be used, which 
may optionally contain gum arabic, talc, polyvinyl pyrroli-
done, carbopol gel, polyethylene glycol, and/or titanium 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 65 
tablets or dragee coatings for identification or to characterize 
different combinations of active compound doses. 
Suspensions of the active compounds may also be pre-
pared as appropriate oily injection suspensions. Suitable 
lipophilic solvents or vehicles include fatty oils such as 
sesame oil and synthetic fatty acid esters, such as ethyl 
oleate or triglycerides, or liposomes. Aqueous injection 
suspensions may contain substances that increase the vis-
cosity of the suspension, such as sodium carboxymethyl 
cellulose, sorbitol, or dextran. Optionally, the suspension 
may also contain suitable stabilizers or agents that increase 
the solubility of the compounds to allow for the preparation 
of highly concentrated solutions. Alternatively, the active 
ingredient may be in powder form for constitution with a 
suitable vehicle, e.g., sterile pyrogen-free water, before use. 
As mentioned above, the compositions of the present 
invention may also be formulated as a depot preparation. 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu-
larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated with suitable poly-
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
US 9,540,327 B2 
15 16 
of the afl.liction, the manner of administration, and the 
judgment of the prescribing physician. 
The present compositions may, if desired, be presented in 
a pack or dispenser device containing one or more unit 
dosage forms containing the active ingredient. Such a pack 
or device may, for example, comprise metal or plastic foil, 
such as a blister pack. The pack or dispenser device may be 
accompanied by instructions for administration. Composi-
tions comprising a compound of the invention formulated in 
a compatible pharmaceutical carrier may also be prepared, 
placed in an appropriate container, and labeled for treatment 
of an indicated condition. 
Suitable carriers for the hydrophobic molecules of the 
invention are well known in the art and include co-solvent 
systems comprising, for example, benzyl alcohol, a nonpolar 
surfactant, a water-miscible organic polymer, and an aque-
ous phase. The co-solvent system may be the VPD co- 5 
solvent system. VPD is a solution of3% w/v benzyl alcohol, 
8% w/v of the nonpolar surfactant polysorbate 80, and 65% 
w/v polyethylene glycol300, made up to volume in absolute 
ethanol. The VPD co-solvent system (VPD:5W) consists of 
VPD diluted 1:1 with a 5% dextrose in water solution. This 10 
co-solvent system is effective in dissolving hydrophobic 
compounds and produces low toxicity upon systemic admin-
istration. Naturally, the proportions of a co-solvent system 
may be varied considerably without destroying its solubility 
and toxicity characteristics. Furthermore, the identity of the 
co-solvent components may be varied. For example, other 
low-toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction size of polyethylene glycol may 
These and other embodiments of the present invention 
will readily occur to those of ordinary skill in the art in view 
15 of the disclosure herein, and are specifically contemplated. 
be varied, other biocompatible polymers may replace poly-
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sug- 20 
ars or polysaccharides may substitute for dextrose. 
Alternatively, other delivery systems for hydrophobic 
molecules may be employed. Liposomes and emulsions are 
well known examples of delivery vehicles or carriers for 
hydrophobic drugs. Liposomal delivery systems are dis- 25 
cussed above in the context of gene-delivery systems. Cer-
tain organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus-
tained-release systems, such as semi-permeable matrices of 30 
solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained-
release materials are established and available to those of 
skill in the art. Sustained-release capsules may, depending 
on their chemical nature, release the compounds for a few 
weeks up to over 100 days. Depending on the chemical 
nature and the biological stability of the therapeutic reagent, 
additional strategies for stabilization may be employed. 
For any composition used in the present methods of 
treatment, a therapeutically effective dose can be estimated 
initially using a variety of techniques well known in the art. 
For example, in a cell culture assay, a dose can be formu-
lated in animal models to achieve a circulating concentration 
range that includes the IC50 as determined in cell culture. 
Dosage ranges appropriate for human subjects can be deter-
mined, for example, using data obtained from cell culture 
assays and other animal studies. 
A therapeutically effective dose of an agent refers to that 
amount of the agent that results in amelioration of symptoms 
35 
40 
45 
or a prolongation of survival in a subject. Toxicity and 
therapeutic efficacy of such molecules can be determined by 50 
standard pharmaceutical procedures in cell cultures or 
experimental animals, e.g., by determining the LD50 (the 
dose lethal to 50% of the population) and the ED 5 0 (the dose 
therapeutically effective in 50% of the population). The dose 
ratio of toxic to therapeutic effects is the therapeutic index, 
55 
which can be expressed as the ratio LD50/ED50 . Agents that 
exhibit high therapeutic indices are preferred. 
Dosages preferably fall within a range of circulating 
concentrations that includes the ED50 with little or no 
toxicity. Dosages may vary within this range depending 
upon the dosage form employed and the route of adminis- 60 
tration utilized. The exact formulation, route of administra-
tion, and dosage should be chosen, according to methods 
known in the art, in view of the specifics of a subject's 
condition. 
The amount of agent or composition administered will, of 65 
course, be dependent on a variety of factors, including the 
sex, age, and weight of the subject being treated, the severity 
EXAMPLES 
The invention is further understood by reference to the 
following examples, which are intended to be purely exem-
plary of the invention. The present invention is not limited 
in scope by the exemplified embodiments, which are 
intended as illustrations of single aspects of the invention 
only. Any methods that are functionally equivalent are 
within the scope of the invention. Various modifications of 
the invention in addition to those described herein will 
become apparent to those skilled in the art from the fore-
going description. Such modifications fall within the scope 
of the appended claims. 
Example 1 
Preparation of 2,2'-(1, 12-dodecanediyl)bispyridine 
Q 
N 
~ 
,-::; 
N 
LDA (2M) (20 mL, 40.00 mmol) was added dropwise to 
a solution of 2-picoline (3.73 g, 40.00 mmol) in THF (60 
mL) at -78° C. The mixture was stirred for 30 min and then 
1,10-diiododecane (6.31 g, 16.00 mmol) in THF (10 mL) 
was added dropwise. The resulting mixture was warmed to 
room temperature and stirred for 4 hrs. 50% saturated 
NH4 Cl was added to the reaction mixture. The aqueous 
phase was extracted with ethylacetate ( 40 mLx2), and the 
combined organic liquors were washed with 50% saturated 
brine ( 40 mLx3) and saturated brine ( 40 mL ), dried over 
anhydrous Na2 S04 , and concentrated under reduced pres-
sure. The crude product was purified by column chroma-
tography (hexanes:ethylacetate 2:1 to 1:1) to afford 3.75 g of 
the title compound. Yield: 72%. 1 H NMR (300 MHz, 
CDC13 ) ll 1.13-1.42 (m, 16H), 1.60-1.81 (m, 4H), 2.78 (t, 
1=7.8 Hz, 4H), 7.08 (ddd, 1=7.5, 5.1, 0.6 Hz, 2H), 7.13 (d, 
1=7.5 Hz, 2H), 7.57 (dt, 1=7.5, 1.8 Hz, 2H), 8.52 (dd, 1=5.1, 
0.6 Hz, 2H) ppm; 13C NMR (75 MHz, CDC13 ) ll29.7, 29.75, 
29.8, 29.9, 30.2, 38.7, 120.9, 122.8, 136.3, 149.2, 162.5 
ppm. 
US 9,540,327 B2 
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Example 2 
Preparation of N,N'-dimethyl-2,2'-(1,12-dode-
canediyl)bispyridinium diiodide 
18 
Example 4 
Preparation of N,N'-dimethyl-3,3'-(1 ,12-dode-
canediyl)bispyridinium diiodide 
1-- ~ 
10 I ~ 
El 
21 
15 
20 2,2'-(1,12-Dodecanediyl)bispyridine (370 mg, 1.14 
mmol) was dissolved in acetone (15 mL). Methyl iodide 
(1.62 g, 11.40 mmol) was added and the mixture was stirred 
for 48 hrs at room temperature. The precipitate was filtered 
and washed with diethyl ether. The obtained pale yellow 
solid was dried under vacuum to give 643 mg of the title 25 
compound. Yield: 93%. 1H NMR (300 MHz, DMSO-d6) o 
1.17-1.50 (m, 16H), 1.60-1.78 (m, 4H), 3.06 (t, 1=7.8 Hz, 
4H), 4.27 (s, 6H), 7.95 (dt, 1=6.9, 1.2 Hz, 2H), 8.01 (d, 1=7.8 
Hz, 2H), 8.49 (dt, 1=7.8, 1.5 Hz, 2H), 8.95 (d, 1=5.7 Hz, 2H) 
ppm; 13C NMR (75 MHz, DMSO-d6) o 26.5, 28.6, 28.7, 30 
28.9, 29.0, 31.8, 45.2, 124.9, 127.6, 144.9, 146.2, 158.3 
ppm. 
Example 3 
35 
Preparation of 3,3'-(1,12-dodecanediyl)bispyridine 
N 
CH3 
I 
N 
~ 
<tll 
~ "'=:::,.. 
<tl 
..;::; 
N 
I 
CH3 
3,3'-(1,12-Dodecanediyl)bispyridine (300 mg, 0.92 
mmol) was dissolved in acetone (10 mL). Methyl iodide 
(1.42 g, 10 mmol) was added and the mixture was stirred for 
12 hrs at room temperature. The precipitate was filtered and 
washed with diethyl ether. The obtained pale yellow solid 
was dried under vacuum to give 505 mg of the title com-
pound. Yield: 90%. 1H NMR (300 MHz, CD30D) o 1.10-
1.45 (m, 16H), 1.64-1.82 (m, 4H), 2.89 (t, 1=7 .8 Hz, 4H), 
4.52 (s, 6H), 8-92 (dd, 1=8.1, 6.0 Hz, 2H), 8.3.1 1~d, 1=8.1 Hz, 2H), 8.84 (d, 1-6.0 Hz, 2H), 9.00 (s, 2H) ppm, C NMR (75 
MHz, CD30D) o 29.0, 29.1, 29.2, 29.3, 30.3, 32.7, 127.7, 
142.6, 144.3, 144.6, 144.9 ppm. 
Example 5 
Preparation of 4,4'-(1,12-dodecanediyl)bispyridine 
u- '"0 N -~ 
I N 
~ "'=:::,.. 
N 45 
N 
I 
# 
LDA (2M) (20.40 mL, 40.80 mmol) was added dropwise 50 
to a solution of 3-picoline (3.80 g, 40.80 mmol) in THF (60 
mL) at -78° C. The mixture was stirred for 30 min and then 
1,10-diiododecane (6.43 g, 16.32 mmol) in THF (10 mL) 
was added dropwise. The resulting mixture was warmed to 
room temperature and stirred for 4 hrs. 50% saturated 
55 
NH4 Cl was added to the reaction mixture. The aqueous 
phase was extracted with ethylacetate ( 40 mLx2), and the 
combined organic liquors were washed with 50% saturated 
brine ( 40 mLx3) and saturated brine ( 40 mL ), dried over 
anhydrous Na2 S04 , and concentrated under reduced pres-
sure. The crude product was purified by column chroma- 60 
tography (hexanes:ethylacetate 2:1 to 1:1) to afford 3.98 g of 
the title compound. Yield: 75%. 1H NMR (300 MHz, 
CDC13 ) o 1.17-1.40 (m, 16H), 1.53-1.68 (m, 4H), 2.60 (t, 
1=7.5 Hz, 4H), 7.20 (dd, 1=7.8, 1.8 Hz, 2H), 7.48 (dt, 1=7.8, 
1.8 Hz, 2H), 8.43 (d, 1=5.1 Hz, 2H), 8.44 (s, 2H) ppm; 13C 65 
NMR (75 MHz, CDC13 ) o29.4, 29.7, 29.8, 29.9, 31.4, 33.3, 
123.3, 135.8, 138.4, 147.2, 150.0 ppm. 
~ N 
I 
~ "'=:::,.. 
I 
N # 
LDA (2M) (20 mL, 40.00 mmol) was added dropwise to 
a solution of 4-picoline (3.73 g, 40.00 mmol) in THF (60 
mL) at -78° C. The mixture was stirred for 30 min and then 
1,10-diiododecane (6.31 g, 16.00 mmol) in THF (10 mL) 
was added dropwise. The resulting mixture was warmed to 
room temperature and stirred for 4 hrs. 50% saturated 
NH4 Cl was added to the reaction mixture. The aqueous 
phase was extracted with ethylacetate ( 40 mLx2), and the 
combined organic liquors were washed with 50% saturated 
brine ( 40 mLx3) and saturated brine ( 40 mL ), dried over 
anhydrous Na2 S04 , and concentrated under reduced pres-
sure. The crude product was purified by column chroma-
tography (hexanes:ethylacetate 1:1 to 1:2) to afford 4.16 g of 
the title compound. Yield: 80%. 1 H NMR (300 MHz, 
CDC13 ) o 1.18-1.40 (m, 16H), 1.53-1.70 (m, 4H), 2.59 (t, 
1=7.5 Hz, 4H), 7.10 (d, 1=6.0 Hz, 4H), 8.48 (d, 1=6.0 Hz, 
4H) ppm; 13C NMR (75 MHz, CDC13 ) o 29.4, 29.7, 29.8, 
29.9, 30.6, 35.5, 124.0, 149.6, 151.8 ppm. 
US 9,540,327 B2 
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Example 6 
Preparation of N,N'-dimethyl-4,4'-(1,12-dode-
canediyl)bispyridinium diiodide 
20 
N 
1-
4,4'-(1,12-Dodecanediyl)bispyridine (340 mg, 1.05 20 
mmol) was dissolved in acetone (15 mL). Methyl iodide 
(1.50 g, 10.6 mmol) was added and the mixture was stirred 
for 12 hrs at room temperature. The precipitate was filtered 
and washed with diethyl ether. The obtained pale yellow 
LDA (2M) (15 mL, 30.00 mmol) was added dropwise to 
a solution of3,5-lutidine (3.38 g, 31.50 mmol) in THF (50 
mL) at -78° C. The mixture was stirred for 30 min and then 
1,10-diiododecane (4.73 g, 12.00 mmol) in THF (10 mL) 
solid was dried under vacuum to give 599 mg of the title 25 was added dropwise. The resulting mixture was warmed to 
compound. Yield: 94%. 1 H NMR (300 MHz, DMSO-d6) o room temperature and stirred for 4 hrs. 50% saturated 
NH4 Cl was added to the reaction mixture. The aqueous 
phase was extracted with ethylacetate ( 40 mLx2), and the 
1.17-1.36 (m, 16H), 1.55-1.71 (m, 4H), 2.86 (t, 1=7.8 Hz, 
4H), 4.28 (s, 6H), 7.98 (d, 1=6.9 Hz, 4H), 8.84 (d, 1=6.6 Hz, 
2H) ppm; 13C NMR (75 MHz, DMSO-d6) o 28.5, 28.7, 
28.9, 29.0, 29.1, 34.5, 47.1, 127.0, 144.5, 161.8 ppm. 30 combined organic liquors were washed with 50% saturated 
Example 7 
Preparation of 
3,3'-(1, 12-dodecanediyl)bis-5-methylpyridine 
u 
N 
brine ( 40 mLx3) and saturated brine ( 40 mL ), dried over 
anhydrous Na2 S04 , and concentrated under reduced pres-
sure. The crude product was purified by column chroma-
35 tography (hexanes:ethylacetate 2:1 to 1:1) to afford 2.82 g of 
the title compound. Yield: 67%. 1 H NMR (300 MHz, 
CDC13 ) o 1.17-1.40 (m, 16H), 1.47-1.68 (m, 4H), 2.30 (s, 
6H), 2.56 (t, 1=7.5 Hz, 4H), 7.29 (s, 2H), 8.24 (s, 2H), 8.25 
(s, 2H) ppm; 13C NMR (75 MHz, CDC13 ) o18.6, 29.5, 29.7, 
40 
29.8, 29.9, 31.5, 33.1, 132.7, 136.5, 137.5, 147.1, 147.7 
ppm. 
45 
Example 8 
Preparation of N,N'-dimethyl-3,3'-(1 ,12-dode-
canediyl)bis-5-methylpyridinium diiodide 
US 9,540,327 B2 
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3,3'-(1,12-Dodecanediyl)bis-5-methylpyridine (300 mg, 
0.92 mmol) was dissolved in acetone (10 mL). Methyl 
iodide (1.42 g, 10 mmol) was added and the mixture was 
stirred for 12 hrs at room temperature. The precipitate was 
filtered and washed with diethyl ether. The obtained pale 5 
yellow solid was dried under vacuum to give 4 77 mg of the 
title compound. Yield: 81%. 1H NMR (300 MHz, CD30D) 
01.12-1.47 (m, 16H), 1.65-1.80 (m, 4H), 2.55 (s, 6H), 2.83 
(t, 1=7.8 Hz, 4H), 4.37 (s, 6H), 8.30 (s, 2H), 8.65 (s, 2H), 
8.69 (s, 2H) ppm; 13C NMR (75 MHz, CD30D) o 18.6, 10 
30.4, 30.6, 30.8, 30.9, 31.7, 33.6, 140.2, 143.3, 143.9, 144.6, 
146.8 ppm. 
Example 9 
Preparation of 
N-methyl-3-(12-bromododecyl)-pyridinium iodide 
() -
N 
Br 
~ -
u 
N 
~ 
Br 
® 
~ ]8 N 
I 
CH3 
LDA (2M) (10.5 mL, 21.22 mmol) was added dropwise to 
15 
20 
25 
30 
35 
a solution of 3-picoline (2.17 g, 23.34 mmol) in THF (60 
mL) at -78° C. The mixture was stirred for 30 min and then 40 
1,11-dibromoundecane (10 g, 31.83 mmol) was added in one 
portion. The resulting mixture was warmed to oo C. and 
stirred for 4 hrs. 50% saturated NH4Cl was added to the 
reaction mixture. The aqueous phase was extracted with 
ethylacetate ( 40 mLx2), and the combined organic liquors 
were washed with 50% saturated brine (40 mLx3) and 
saturated brine (40 mL), dried over anhydrous Na2 S04 , and 
concentrated under reduced pressure. The crude product was 
purified by colunm chromatography (hexanes:ethylacetate 
4:1) to afford 4.47 g 3-(12-bromododecyl)-pyridine. Yield: 
59%. 
45 
50 
The above product (960 mg, 2.95 mmol) was dissolved in 
acetone (15 mL). Methyl iodide (2 g, 10.41 mmol) was 
added and the mixture was stirred for 12 hrs at room 
temperature. The solvent was removed. The residue was 
suspended in diethyl ether, filtered, and washed with diethyl 
ether. The obtained pale yellow solid was dried under 
vacuum to give 1.28 of the title compound. Yield: 93%. 1 H 
NMR (300 MHz, CDC13 ) 61.13-1.47 (m, 16H), 1.63-1.90 
(m, 4H), 2.89 (t, 1=7.8 Hz, 2H), 3.19 (t, 1=6.9 Hz, 2H), 4.70 
55 
60 
(s, 3H), 8.04 (dd, 1=7.8, 6.0 Hz, lH), 8.25 (d, 1=7.8 Hz, lH), 
9.15 (s, lH), 9.20 (s, 1=6.0 Hz, lH) ppm; 13C NMR (75 
MHz, CDC13 ) o 7.8, 28.7, 29.4, 29.5, 29.6, 29.67, 29.70, 65 
29.74, 30.6, 30.7, 33.0, 33.8, 49.6, 127.9, 143.1, 144.2, 
144.8 ppm. 
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Example 10 
Preparation of 1-methyl-3-(12-(3-methylpyridin-1-
ium-1-yl)dodecyl)pyridin-1-ium mono-bromide 
mono-iodide 
~ 
® 
u 
N 
I 
CH3 
~ 
® 
u 
N 
I 
CH3 
]8 
Br -
~ 
N~ 
A mixture of N-methyl-3 -( 12-bromododecy 1)-pyridinium 
iodide (315 mg, 0.67 mmol), 3-picoline (1 mL) and 
butanone (5 mL) was heated at 80° C. for 24 hrs. Solvent 
was removed under reduced pressure. The resulted mixture 
was washed with diethyl ether and then dissolved in water 
(10 mL), the aqueous solution was extracted with chloro-
form (15 mLx3). Water was removed by lyophilization to 
afford 325 mg of the title compound. Yield: 86%. 1 H NMR 
(300 MHz, CD30D) o 1.23-1.50 (m, 16H), 1.66-1.81 (m, 
2H), 1.94-2.12 (m, 2H), 2.60 (s, 3H), 2.88 (t, 1=7.8 Hz, 2H), 
4.43 (s, 3H), 4.63 (t, 1=7.5 Hz, 2H), 7.97-8.05 (m, 2H), 8.45 
(t, 1=6.9 Hz, 2H), 8.77 (d, 1=6.0 Hz, lH), 8.87 (d, 1=7.8 Hz, 
lH), 8.89 (s, lH), 9.00 (s, lH) ppm; 13C NMR (75 MHz, 
CD30D) o 18.8, 27.3, 30.2, 30.3, 30.55, 30.6, 30.7, 30.8, 
31.7, 32.6, 33.7, 63.0, 128.6, 128.7, 141.2, 143.0, 144.1, 
145.3, 145.5, 146.2, 146.3, 147.2 ppm. 
Example 11 
Preparation of 3,5-dimethyl-1-(12-(1-methylpyridin-
1-ium-3-yl)dodecyl)pyridin-1-ium mono-bromide 
mono-iodide 
~ 
® 
u 
N 
I 
CH3 
~ 
® 
u 
N 
I 
CH3 
]0 
]0 
Br -
~ 
E~ 
A mixture of N-methyl-3 -( 12-bromododecy 1)-pyridinium 
iodide (285 mg, 0.61 mmol), 3,5-lutidine (1 mL) and 
butanone (5 mL) was heated at 80° C. for 24 hrs. Solvent 
was removed under reduced pressure. The resulted mixture 
was washed with diethyl ether and then dissolved in water 
(10 mL), the aqueous solution was extracted with chloro-
US 9,540,327 B2 
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form (15 mLx3). Water was removed by lyophilization to 
afford 319 mg of the title compound. Yield: 91%. 1H NMR 
(300 MHz, CD30D) o 1.23-1.48 (m, 16H), 1.68-1.82 (m, 
2H), 1.93-2.10 (m, 2H), 2.55 (s, 6H), 2.88 (t, 1=7.8 Hz, 2H), 
4.41 (s, 3H), 4.55 (t, 1=7.5 Hz, 2H), 8.00 (dd, 1=7.8, 6.0 Hz, 5 
lH), 8.27 (s, lH), 8.45 (d, 1=7.8 Hz, lH), 8.75 (s, 2H), 8.76 
(d, 1=6.0 Hz, lH), 8.88 (s, lH) ppm; 13C NMR (75 MHz, 
CD30D) o 18.5, 27.4, 30.28, 30.3, 30.6, 30.64, 30.7, 30.8, 
31.7, 32.7, 33.7, 62.8, 128.7, 140.4, 142.7, 144.1, 145.4, 
-continued 
~ 
~v 
146.3, 147.8 ppm. 
Example 12 
Preparation of (S)-1-methyl-3-(12-(3-(1-methylpyr-
rolidin-2-yl)pyridin-1-ium-1-yl)dodecyl)pyridin-1-
ium mono-bromide mono-iodide 
Br -
0 I 
N ''···o 
Br0 H3C_..N 
A mixture of N-methyl-3-(12-bromododecyl)-pyridinium 
iodide (250 mg, 0.53 mmol), S-nicotine (1 mL) and 
butanone (5 mL) was heated at 80° C. for 24 hrs. Solvent 
was removed under reduced pressure. The resulted mixture 
was washed with diethyl ether and then dissolved in water 
(10 mL), the aqueous solution was extracted with chloro-
form (15 mLx3). Water was removed by lyophilization to 
afford 270 mg of the title compound. Yield: 81%. 1H NMR 
(300 MHz, CD30D) o 1.15-1.40 (m, 16H), 1.62-1.77 (m, 
2H), 1.80-2.10 (m, 5H), 2.23 (s, 3H), 2.35-2.56 (m, 2H), 
2.87 (t, 1=7.8 Hz, 2H), 3.32 (m, lH), 3.58 (t, 1=8.4 Hz, lH), 
4.37 (s, 3H), 4.64 (t, 1=7.5 Hz, 2H), 7.95 (dd, 1=8.1, 6.3 Hz, 
lH), 8.09 (dd, 1=8.1, 6.3 Hz, lH), 8.40 (d, 1=7.8 Hz, lH), 
8.53 (d, 1=8.1 Hz, lH), 8.61 (d, 1=6.0 Hz, lH), 8.68 (s, lH), 
8.82 (d, 1=6.9 Hz, lH), 8.83 (s, lH) ppm; 13C NMR (75 
MHz, CD30D) o 22.4, 25.4, 28.3, 28.7, 28.8, 28.9, 29.0, 
29.9, 30.8, 32.2, 34.0, 39.5, 48.2, 56.7, 62.3, 67.6, 127.5, 
128.5, 142.4, 143.4, 143.5, 143.7, 144.2, 144.5, 144.6, 145.2 
ppm. 
Example 13 
Preparation of 1-methyl-3-(12-(pyridin-1-ium-1-yl) 
dodecyl)pyridin-1-ium mono-bromide mono-iodide 
Br -
10 
A mixture of N-methyl-3 -( 12-bromododecy 1)-pyridinium 
iodide (250 mg, 0.53 mmol), pyridine (1 mL) and butanone 
(5 mL) was heated at 80° C. for 24 hrs. Solvent was removed 
under reduced pressure. The resulted mixture was washed 
with diethyl ether and then dissolved in water (10 mL), the 
15 aqueous solution was extracted with chloroform (15 mLx3). 
20 
25 
30 
Water was removed by lyophilization to afford 278 mg of the 
title compound. Yield: 95%. 1 H NMR (300 MHz, CD30D) 
o1.20-1.50 (m, 16H), 1.65-1.82 (m, 2H), 1.95-2.12 (m, 2H), 
2.88 (t, 1=7.8 Hz, 2H), 4.42 (s, 3H), 4.68 (t, 1=7.5 Hz, 2H), 
8.00 (t, 1=6.9 Hz, lH), 8.14 (t, 1=6.9 Hz, 2H), 8.45 (d, 1=7.8 
Hz, lH), 8.62 (t, 1=7.8 Hz, lH), 8.76 (d, 1=6.0 Hz, lH), 8.88 
(s, lH), 9.07 (d, 1=5.4 Hz, 2H) ppm; 13C NMR (75 MHz, 
CD30D) o 27.3, 30.2, 30.3, 30.6, 30.63, 30.7, 30.8, 31.7, 
32.7, 33.7, 63.2, 128.7, 129.5, 144.1, 145.3, 145.9, 146.2, 
146.3, 146.8 ppm. 
Example 14 
Inhibition of [3H]NIC and [3H]Methyllycaconitine 
Binding Assays 
Whole brain, excluding cortex and cerebellum, was 
homogenized in 20 vol of ice-cold buffer, containing (in 
mM): 2 HEPES, 11.8 NaCl, 0.48 KCl, 0.25 CaC12 and 0.12 
MgS04 , pH 7.5. Homogenate was centrifuged (25,000 g, 15 
35 min, 4° C.). Pellets were resuspended in 20 vol buffer and 
incubated at 37° C., for 10 min, cooled to 4° C. and 
centrifuged (25,000 g, 15 min, 4° C.). Pellets were resus-
pended and centrifuged using the same conditions. Final 
pellets were stored in assay buffer, containing (in mM): 20 
40 HEPES, 118 NaCl, 4.8 KCl, 2.5 CaC12 , and 1.2 MgS04 , pH 
7.5 at -70° C. Upon use, final pellets were resuspended in 
-20 vol assay buffer. Samples (250 fll) contained 100-140 flg 
of membrane protein, 3 nM [3H]nicotine or 3 nM [3 H] 
methyllycaconitine, and analog (1 00 nM) in assay buffer 
45 containing 50 mM Tris. Control was in the absence of 
analog. In [3 H]nicotine and [3 H]methyllycaconitine binding 
assays, nonspecific binding was determined in the presence 
of 10 f.LM cytisine and 10 f.LM nicotine, respectively. Incu-
bations proceeded for 60 min at room temperature using 
96-well plates and were terminated by harvesting on Uni-
50 filter-96 GF/B filter plates presoaked in 0.5% polyethylen-
imine, using a Packard FilterMate harvester. After washing 
5 times with 350 fll ice-cold assay buffer, filter plates were 
dried (60 min, 4° C.), bottom-sealed, and filled with Pack-
ard's MicroScint 20 cocktail ( 40 fll/well). After 60 min, filter 
55 plates were top-sealed, and radioactivity determined using a 
Packard TopCount. Protein concentrations were determined 
using the Bradford dye-binding procedure bovine serum 
albumin as the standard. The results are summarized in Table 
1. 
60 
65 
Example 15 
Inhibition of Nicotine-Evoked [3 H]Neurotransmitter 
Release Assay 
The [3 H]dopamine overflow assay using superfused rat 
striatal slices preloaded with [3 H]dopamine was used to 
US 9,540,327 B2 
25 
determine the ability of a probe concentration (100 nM) of 
each his-quaternary ammonium analog to inhibited nicotine-
evoked [3 H]dopamine overflow. Briefly, coronal slices of rat 
striata (500 fllll, 6-8 mg) were obtained using a Mcilwain 
tissue chopper. Slices were incubated for 30 min in Krebs' 
buffer (in mM: 118 NaCl, 4.7 KCl, 1.2 MgC12 , 1.0 
NaH2P04 , 1.3 CaC12 , 11.1 a-D-glucose, 25 NaHC03 , 0.11 
L-ascorbic acid and 0.004 ethylenediaminetetraacetic acid 
(EDTA), pH 7.4, saturated with 95% 0 2/5% C02 ) at 34° C. 
in a metabolic shaker. Slices were then incubated for an 
3 10 
additional 30 min in fresh buffer containing 0.1 f.LM [ H] 
dopamine. After rinsing, each slice was transferred to each 
one of 20 superfusion chambers, maintained at 34 o C. and 
superfused (0.6 ml/min) with oxygenated Krebs' buffer in a 
Brandel Suprafusion 2500 (Biomedical Research and Devel-
opment Laboratories, Inc., Gaithersburg, Md.). The buffer 15 
contained both nomifensine (1 0 f.LM), a dopamine uptake 
blocker, and pargyline (10 f.LM), a monoamine oxidase 
inhibitor, ensuring that [3 H]overflow primarily represented 
[
3H]dopamine, rather than [3 H]metabolites. Following 
superfusion for 60 min, two 4-min samples (2.4 ml/sample) 20 
were collected to determine basal [3H]outflow. After collec-
tion of the second basal sample, slices from an individual rat 
were superfused for 40 min in the absence (0 nM; control) 
or presence of each his-quaternary ammonium analog (1 00 
nM) to determine the intrinsic activity of the analog, i.e., 25 
ability of the analog to evoke [3H]overflow. Following 40 
min of superfusion in the absence or presence of analog, 
nicotine (10 f.LM) was added to the superfusion buffer and 
samples were collected for an additional 40 min to deter-
r~Jed~~~~!i%v~~~~. ~a~~~si0o~~~~~~t~~c~l~i~:-i:v~~~~ 30 
experiment was superfused for 40 min in the absence of 
analog, followed by superfusion with 10 f.LM nicotine to 
determine nicotine-evoked [3 H]dopamine overflow in the 
absence of analog (nicotine control). After collection of the 
superfusate samples, the slices were retrieved from the 35 
chambers and solubilized using 1 ml of TS-2 tissue solubi-
lizer. Scintillation cocktail ( 4 ml) was added to the super-
fusate samples. The pH and volume of the solubilized tissue 
samples were adjusted to that of the superfusate samples. 
Radioactivity in the superfusate and tissue samples was 40 
determined by liquid scintillation spectroscopy (Packard 
model B 1600 TR Scintillation Counter, Downer's Grove, 
Ill.). 
For individual analogs, a complete concentration response 
was determined using the following methodology. Rat stri- 45 
atal slices (500 f.tm thickness, 6-8 mg wet weight) were 
incubated for 30 minutes in Krebs buffer (118 mM NaCl, 4.7 
mM KCl, 1.2 mM MgC12 , 1.0 mM NaH2 P04 , 1.3 mM 
26 
CaC12 , 11.1 mM glucose, 25 mM NaHC03 , 0.11 mM 
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4, 
and saturated with 95% 0i5% C02 ) in a metabolic shaker 
at 34 o C. Slices were rinsed with 15 mL of fresh buffer and 
incubated for an additional 30 minutes in fresh buffer 
containing 0.1 f.LM [3H]dopamine (DA; 6 slices/3 mL). 
Subsequently, slices were rinsed with 15 mL of fresh buffer 
and transferred to a glass superfusion chamber. Slices were 
superfused (1.0 mL/min) for 60 minutes with Krebs buffer 
containing nomifensine (10 f.LM) and pargyline (10 f.LM) and 
maintained at 34° C., pH 7.4, with continual aeration (95% 
0 2/5% C02 ). Three 5-minute samples (5 mL each) were 
collected to determine basal outflow of [3 H]DA. The his-
quaternary analogs were added to the superfusion buffer 
after the collection of the third sample and remained in the 
buffer until 12 consecutive five minute samples were col-
lected. Subsequently, S-(-)-nicotine (1 0 f.LM) was added to 
the buffer and an additional 12 consecutive five minute 
samples were collected. At the end of the experiment, each 
slice was solubilized and the [3H] content of the tissue 
determined. Radioactivity in the superfusate and tissue 
samples was determined by liquid scintillation spectroscopy. 
Fractional release for tritium collected in each sample was 
divided by the total tritium present in the tissue at the time 
of sample collection and was expressed as a percentage of 
total tritium. Basal [3 H]outflow was calculated from the 
average of the tritium collected in the two five minute 
samples just before addition of the quaternary analog. The 
sum of the increase in collected tritium resulting from either 
exposure to the test compound or exposure to S(-)nicotine 
in the absence and presence of the test compound equaled 
total [3H]overflow. [3H]Overflow was calculated by sub-
tracting the [3H]outflow during an equivalent period of 
prestimulation from the values in samples collected during 
and after drug exposure. Inasmuch as the radiolabelled 
compounds were not separated and identified, the tritium 
collected in superfusate is referred to as either [3H]outflow 
or [3 H]overflow, rather than as [3H]dopamine. [3H]Overflow 
primarily represents [3 H]dopamine in the presence of 
nomifensine and pargyline in the superfusion buffer. 
All of the his-quaternary analogs were evaluated for their 
ability to evoke [3 H]dopamine release from rat striatal slices 
using the probe 100 nM concentration (Table 1). None of the 
compounds examined had any significant [3 H]dopamine 
releasing properties in this assay in the concentration range 
tested. One analog GZ527B was evaluated for full concen-
tration dependent inhibition of the effect of nicotine to evoke 
[
3 H]dopamine release (FIG. 1). In both studies, the antago-
nist activity was evaluated by comparing the NIC-evoked 
[
3 H]overflow in the absence and presence of the analogs. 
TABLE 1 
his-Quaternary Ammonium Salts Inhibition of [3H]NIC and ['H]MLA Binding to 
Rat Striatal Nicotinic Receptors and Nicotine-evoked [3H]Dopamine Release from 
Superfused Rat Striatal Slices 
COMPOUND 
Inhibition of 
[
3 H]Nicotine 
binding 
Ki(f!M; 
M ± SEM) 
8.20 ± 1.78 
Inhibition of 
[
3H]MLA 
Binding 
Ki(f!M; 
M ± SEM) 
>100 
Inhibition 
Nicotine-
evoked 
['H]DA 
release 
(% 
inhibition at 
100 nM) 
32% 
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TABLE !-continued 
his-Quaternary Ammonium Salts Inhibition of [3 H]NIC and [3H]MLA Binding to 
Rat Striatal Nicotinic Receptors and Nicotine-evoked [3 H]Dopamine Release from 
Superfused Rat Striatal Slices 
COMPOUND 
GZ-527A 
H;C/~'-m, 
2I 
GZ-527B 
CH3 
2
Ie CH3 
~ 
GZ-528A 
GZ-528B 
~u 
N e 
I I e 
CH3 Br 
GZ-529A 
~Ny0: 
I I e 
CH3 Br 
GZ-529B 
~cAH; 
N e 
I I e 
CH3 Br 
GZ-530A 
~0 
N e 
I I e 
CH3 Br 
GZ-530B 
Inhibition of 
[
3 H]Nicotine 
binding 
Ki (f]M; 
M ± SEM) 
7.88 ± 1.68 
8.17±0.17 
>100 
>100 
>100 
6.62 ± 1.14 
23.4 ± 3.94 
Inhibition of 
[
3H]MLA 
Binding 
Ki(f!M; 
M ± SEM) 
>100 
>100 
>100 
>100 
>100 
>100 
>100 
Inhibition 
Nicotine-
evoked 
[
3H]DA 
release 
(% 
inhibition at 
100 nM) 
67% 
49% 
30% 
43% 
25% 
43% 
9% 
28 
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aData are % inhibition at 100 nM concentration of the 
his-quaternary analogs for at least 1-3 independent experi-
ments. Specific binding in the [3H]NIC binding assay is 
calculated as the difference between the total binding of 3 
nM [3H]NIC and nonspecific binding in the presence of 10 5 
f.LM cytisine. Specific binding for the [3H]MLA binding 
assay is calculated as the difference between the total 
binding of 3 nM [3H]MLA to the receptors alone and its 
nonspecific binding in the presence of 10 f.LM nicotine. 
Analog-induced inhibition of nicotine-evoked [3H]DA 10 
release is calculated as a percent of that in the absence of the 
his-quaternary anmwnium analog. 
It will be appreciated that, although specific embodiments 
of the invention have been described herein for purposes of 
illustration, various modifications may be made without 15 
departing from the spirit and scope of the invention. All such 
modifications and variations are intended to be included 
herein within the scope of this disclosure and the present 
invention and protected by the following claims. 
We claim: 20 
1. A his-quaternary monium compound of Formula (I) 
X 2 8EBR2-R-R1EB8X 1 (I) 
wherein X18 and X28 are each independently an organic 
or inorganic anion; 
wherein R is selected from the group consisting of 
-(CH2)12-; 
wherein R 1 and R 2 are each six membered rings as shown 
25 
in formula (IIA), wherein each ring of R1 and R2 has 
one quaternized nitrogen atom, and the ring atoms from 30 
R1 and R2 which are attached to R cannot both be 
nitrogen atoms: 
(!lA) 35 
30 
Y5 are each independently selected from hydrogen, 
alkyl, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, ary-
lalkyl, arylalkenyl, arylalkynyl, acyl, alkylsulfonyl, 
arylsulfonyl, or heterocyclic, where if Y4 or Y5 com-
prises alkenyl or alkynyl, the site ofunsaturation is not 
conjugated with the nitrogen; SY6 , where Y6 is selected 
from hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, 
aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl, or 
heterocyclic, and where if Y6 comprises alkenyl or 
alkynyl, the site ofunsaturation is not conjugated with 
the sulfur; and any of R 5 , R 7 , R9 , R u, or R 13 attached 
to the quaternized nitrogen is independently a straight 
or branched alkyl group of four carbons or fewer. 
2. The compound of claim 1, wherein: 
R is -(CH2 ) 12-; 
R1 and R2 are pyridinium rings; 
A3 is nitrogen; 
R7 is methyl; 
Ru is hydrogen or methyl; and 
X1 and X2 are bromide or iodide. 
3. The compound of claim 1, wherein: 
R is -(CH2 ) 12-; 
R1 and R2 are pyridinium rings; 
A 4 is nitrogen; 
R9 is methyl; and 
X1 and X2 are bromide or iodide. 
4. The compound of claim 1, wherein: 
R is -(CH2 ) 12-; 
R1 and R2 are pyridinium rings; 
wherein for R1, A3 is nitrogen, R7 is methyl, Ru is 
hydrogen or methyl, and X1 is bromide or iodide; and 
wherein for R2, A1 is nitrogen, R7 and Ru is hydrogen, 
methyl or 1-methyl-2-pyrrolidinyl, and X2 is bromide 
or iodide. 
5. The compound of claim 1 selected from the group 
40 consisting of: 
wherein one of A 1, A3, and A 4 , is nitrogen and the 
remaining A\ A2, A3, A4 , A5 , and A6 are carbon; 45 
wherein R5 , R7 , R9 , Ru, and R13 are each independently 
selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted 
aryl, alkylaryl, substituted alkylaryl, arylalkyl, substi- 50 
tuted arylalkyl, arylalkenyl, substituted arylalkenyl, 
arylalkynyl, substituted arylalkynyl, halo, cyano, nitro, 
SOY\ S02 Y\ S020Y
1 or S02NHY
1, where Y1 is 
selected from hydrogen, lower alkyl, alkenyl, alkynyl 
or aryl, and where Y1 is not hydrogen in SOY1 and if 55 
Y1 is alkenyl or alkynyl, the site ofunsaturation is not 
conjugated with a heteroatom; COY2, where Y2 is 
selected from hydrogen, alkyl, cycloalkyl, alkoxy, alk-
enyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, 
arylalkynyl, or heterocyclic, and where ifY2 comprises 60 
alkenyl or alkynyl, the site of unsaturation is not 
conjugated with the carbonyl group; OY3, where Y3 is 
selected from hydrogen, alkyl, cycloalkyl, alkenyl, 
alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylal-
kynyl, acyl, alkylsulfonyl, or heterocyclic, where ifY3 65 
comprises alkenyl or alkynyl, the site ofunsaturation is 
not conjugated with the oxygen; NY4Y5 , where Y4 and 
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bispyridinium 
diiodide; 
N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium 
diiodide; 
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bis-5-methylpyri-
dinium diiodide; 
1-methyl-3-(12-(3-methylpyridin-1-ium-1-yl)dodecyl) 
pyridin -1-ium mono-bromide mono-iodide; 
3,5-dimethyl-1-(12-(1-methylpyridin-1-ium-3-yl)dode-
cyl)pyridin-1-ium mono-bromide mono-iodide; and 
1-methyl-3-(12-(pyridin-1-ium-1-yl)dodecyl)pyridin-1-
ium mono-bromide mono-iodide. 
6. A his-quaternary ammonium compound of Formula (I) 
(I) 
wherein X18 and X28 are each independently an organic 
or inorganic anion; 
wherein R is selected from the group consisting of 
-(CH2)12-; 
wherein R 1 and R 2 are each six membered rings as shown 
in formula (IIA), wherein each ring of R1 and R2 has 
one quaternized nitrogen atom, and the ring atoms from 
R1 and R2 which are attached to R cannot both be 
nitrogen atoms: 
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(IIA) 
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N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium 
diiodide; 
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bis-5-methylpyri-
dinium diiodide; 
1-methyl-3-(12-(3-methylpyridin-1-ium-1-yl)dodecyl) 
pyridin-1-ium mono-bromide mono-iodide· 
3,5-dimethyl-1-(12-(1-methylpyridin-1-ium-3~yl)dode­
cyl)pyridin-1-ium mono-bromide mono-iodide· 
10 
wherein one of A1 , A3 , and A4 is nitrogen and the 
(S )-1.-methyl-3 -( 12-(3 -( 1-methylpyrrolidin-2-y l)p~ridin-
1-mm-1-yl)dodecyl)pyridin-1-ium mono-bromide 
mono-iodide; and 
1-methyl-3-(12-(pyridin-1-ium-1-yl)dodecyl)pyridin-1-
ium mono-bromide mono-iodide 
remaining A\ A\ A3 , A4 , A5 , and A6 are carbon· 
h · Rs R7 R9 Ru d 13 ' w erem , , , , an R are each independently 
sel~c~ed from hydrogen, methyl, and 1-methyl-2-pyr-
rohdmyl; and any ofR5 , R7, or R9, when attached to the 
quaternized nitrogen, is independently a straight or 
15 
branched lower alkyl group. 
wherei1_1 t~e sub~tan~e abuse is sel~cted from the group 
cons1stmg of mcotme abuse, cocaine abuse, and alcohol 
abuse. 
15. The method for treating substance abuse according to 
~!aim 14, wherein the his-quaternary ammonium compound 
1s selected from the group consisting of: 
. 7. .CS)-1-methyl-3-(12-(3-(1-methylpyrrolidin-2-yl)pyri-
dm-1-mm-1-yl)dodecyl)pyridin-1-ium mono-bromide 
mono-iodide. 
8. A c?mposition comprising a pharmaceutically accept-
able earner and a compound of claim 1. 
9. A c?mposition comprising a pharmaceutically accept-
able earner and a compound of claim 2. 
10. A ~omposition comprising a pharmaceutically accept-
able earner and a compound of claim 3. 
25 
20 N,N'-dimethyl-2,2'-(1,12-dodecanediyl)bispyridinium 
diiodide; 
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bispyridinium 
diiodide; 
N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium 
diiodide; 
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bis-5-methylpyri-
dinium diiodide; 
1-methyl-3-(12-(3-methylpyridin-1-ium-1-yl)dodecyl) 
pyridin-1-ium mono-bromide mono-iodide· 
3,5-dimethyl-1-(12-(1-methylpyridin-1-ium-3~yl)dode­
cyl)pyridin-1-ium mono-bromide mono-iodide· and 
(S)-1-methyl-3-(12-(3-(1-methylpyrrolidin-2-yl)p~ridin-
11. A ~omposition comprising a pharmaceutically accept-
able earner and a compound of claim 4. 
12. A ~omposition comprising a pharmaceutically accept-
able earner and a compound of claim 5. 
13. A ~omposition comprising a pharmaceutically accept- 30 
able earner and a compound of claim 7. 
1~ . . A ~ethod for treating substance abuse comprising 
admm1stenng to a mammalian subject in need thereof a 
t~erapeutically effective amount of a his-quaternary ammo-
mum compound selected from the group consisting of: 
35 
N,N'-dimethyl-2,2'-(1,12-dodecanediyl)bispyridinium 
diiodide; 
N,N'-dimethyl-3,3'-(1,12-dodecanediyl)bispyridinium 
diiodide; 
1-ium-1-yl)dodecyl)pyridin-1-ium mono-bromide 
mono-iodide. 
16. The method for treating substance abuse according to 
claim 14, wherein the his-quaternary ammonium compound 
is N,N'-dimethyl-4,4'-(1,12-dodecanediyl)bispyridinium 
diiodide. 
* * * * * 
